(The following press release from Schroders was received by e-mail. The
sender verified the statement.)
Schroders notes with disappointment the quick rejection by the AstraZeneca
Board of the latest offer from Pfizer and the decision of the Pfizer Board to
draw a premature end to these negotiations by calling their latest proposal
Final. As long term shareholders, we are strong believers in AstraZeneca and
the potential for its innovative growth pipeline, however, given the increase
in the offer we would encourage the AstraZeneca management to recommence their
engagement with Pfizer, and subsequently their shareholders.
Press spacebar to pause and continue. Press esc to stop.